New hope for Platinum-Resistant ovarian cancer: PLX038 trial launches
NCT ID NCT05465941
First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 4 times
Summary
This Phase II trial tests a drug called PLX038 in 43 people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based chemotherapy. The drug works by blocking enzymes that help cancer cells grow. Researchers will check if it shrinks tumors and how long it keeps the cancer from progressing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PLX038 (a chemotherapy drug)
- What this could lead to
- If it works, this could offer a new treatment option for patients whose ovarian cancer has stopped responding to platinum-based chemotherapy.
- What could go wrong
- This is an early Phase II trial with only 43 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered immune cells take aim at Hard-to-Treat cancers
- Immune cells Re-Trained to fight Drug-Resistant ovarian cancer
- Immune cells retrained to hunt ovarian cancer in new trial
- New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches
- New drug azenosertib takes on Chemo-Resistant ovarian cancer in phase 3 trial